Chu Yu-Waye 4
4 · CytomX Therapeutics, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
CytomX (CTMX) CMO Chu Yu-Waye Sells 21,279 Shares
What Happened
- Chu Yu-Waye, Chief Medical Officer of CytomX Therapeutics (CTMX), sold 21,279 shares on 2026-03-17 at $6.42 per share, generating proceeds of $136,675. The Form 4 lists the transaction as a sale (code S).
Key Details
- Transaction date and price: 2026-03-17, 21,279 shares at $6.42 each.
- Total proceeds: $136,675.
- Shares owned after transaction: filing notes beneficial holdings that include 149,833 RSUs (per footnote F2).
- Footnote: F1 states the shares were sold solely to satisfy tax or other government withholding obligations in connection with RSU vesting.
- Filing: Form filed 2026-03-19 (filed within the normal reporting window in this case).
Context
- This was a tax-withholding sale tied to RSU vesting (routine disposition), not necessarily a discretionary sale signaling a change in insider sentiment. Sales to cover taxes are common following equity awards.
Insider Transaction Report
Form 4
Chu Yu-Waye
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-17$6.42/sh−21,279$136,675→ 189,446 total
Footnotes (2)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F2]Includes 149,833 RSUs.
Signature
/s/ Christopher Ogden, as Attorney-in-Fact for Yu-Waye Chu|2026-03-19